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Edited by Laszlo NagyAbstract We screened active compounds from natural marine
products able to increase PPARa/c transcriptional activity.
Sargaquinoic acid (SQA) and sargahydroquinoic acid (SHQA)
from Sargassum yezoense were identiﬁed as novel PPARa/c dual
agonists. The binding aﬃnity of SQA with PPARc was higher
than that of the speciﬁc PPARc agonist troglitazone, leading
to an activation of PPARc transcriptional activity. In parallel,
treatment of 3T3-L1 cells with SQA and SHQA led to an in-
crease in adipocyte diﬀerentiation and increased expression of
adipogenic marker genes such as aP2, PPARc, resistin, adipo-
nectin, C/EBPa and Glut4. Collectively, our data suggest that
SQA and SHQA are novel PPARa/c dual agonists and may
be beneﬁcial for reducing insulin resistance through regulation
of adipogenesis.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Peroxisome proliferator-activated receptors (PPARs) are
members of the nuclear hormone receptor superfamily of li-
gand-activated transcription factors, and are currently appreci-
ated as potential therapeutic targets for the treatment of
diabetes and dyslipidemia [1]. There are three isotypes of
PPAR, PPARa, PPARb/d (PPARd) and PPARc, encoded by
three separate genes and displaying distinctly diﬀerent tissue
distributions and functions. The PPARa receptor is mainly ex-
pressed in the liver and alters genes associated with fatty acid
oxidation and lipid metabolism [2]. PPARd is associated with
development, embryo implantation, myelination of the corpus
callosum, lipid metabolism and epidermal cell proliferation [3].
On the other hand, the PPARc receptor, predominantly ex-
pressed in the adipose tissue and macrophages, aﬀects genes in-*Corresponding author. Fax: +82 33 641 1074.
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activation of PPARc promotes adipocyte diﬀerentiation as
well as increases insulin sensitivity [5].
Speciﬁc agonists of PPARa (e.g., fenoﬁbrate and gemﬁbro-
zil) have been used to treat dyslipidemia by lowering the free
triglyceride plasma concentration, and PPARc agonists (e.g.,
thiazolidinedions including rosiglitazone and pioglitazone)
are used to treat type-2 diabetes [6]. However, PPARc agonists
exert a variety of side eﬀects, mainly weight gain due to edema
and increased fat mass [7]. These side eﬀects may be circum-
vented through the combined activation of PPARa/c, which
is known to result in a complementary and synergistic increase
in lipid metabolism and insulin sensitivity [8]. As such, phar-
maceutical trials are ongoing to develop dual PPARa/c ago-
nists that possess the beneﬁcial metabolic eﬀects of both
PPARa and -c activation but with fewer side eﬀects. Muraglit-
azar, tesaglitazar, KRP-297 (MK-767), and TAK-559 are cur-
rently being investigated as dual PPARa/c agonists, having
eﬃcacy in glucose normalization and correction of lipid abnor-
malities in diabetic patients [9,10]. However, further develop-
ment of muraglitazar and tesaglitazar failed at clinical trials,
due to their unexpected cardiovascular and renal toxicities
[11,12].
Natural marine products provide a rich source of chemical
diversity that can be used to design and develop new and
potentially useful therapeutic agents [13]. In this study, we
therefore screened active compounds from natural marine
products able to increase PPARa/c transcriptional activity.
We identiﬁed two major active compounds able to activate
PPARa/c, namely sargaquinoic acid (SQA) and sargahydro-
quinoic acid (SHQA) from Sargassum yezoense. In addition,
these two compounds stimulate adipocyte diﬀerentiation
through increasing adipogenic gene expression, which provides
a molecular rationale for further development of SQA and
SHQA for treatment of metabolic disorders.2. Materials and methods
2.1. Preparation of natural marine product extracts
Natural marine products were collected from the seashore of
Gangwon Province, Republic of Korea, and identiﬁed via a voucher
specimen deposited at Kwandong University College of Medicine
(Table 1). The natural marine products were homogenized and crudeblished by Elsevier B.V. All rights reserved.
Table 1
Eﬀect of natural marine product extracts on PPARa/c transcriptional activity
Code no. Scientiﬁc name Family name % Activation*
PPARa PPARc
KD-01 Delesseria serrulata Delesseriaceae 27.3 26.0
KD-02 Chrysymenia wrightii Rhodymeniaceae 31.0 21.7
KD-03 Scytosiphon lomentaria Scytosiphonaceae 24.6 18.6
KD-04 Enteromorpha linza Ulvaceae 21.8 31.2
KD-05 Lomentaria catenata Lomentariaceae 28.4 28.2
KD-07 Acrosorium polyneurum Delesseriaceae 19.1 <5
KD-08 Phyllospadix sp. Cymodoceaceae 36.4 16.3
KD-09 Plocamium telfairiae Plocamiaceae 17.6 9.2
KD-10 Desmarestia ligulata Desmarestiaceae 47.2 14.9
KD-11 Suberites domumcula Suberitidae 32.9 12.9
KD-12 Ahnfeltiopsis ﬂabelliformis Phyllophoraceae 50.4 <5
KD-13 Sargassum confusum Sargassaceae 26.1 6.2
KD-14 Grateloupia elliptica Halymeniaceae 41.4 15.1
KD-15 Eisenia bicyclis Lessoniaceae 10.2 <5
KD-16 Eisenia bicyclis Lessoniaceae 18.5 <5
KD-17 Chondracanthus tenellus Gigartinaceae 32.4 25.9
KD-18 Dictyota dichotoma Dictyotaceae 32.3 22.1
KD-19 Endarachne binghamiae Scytosiphonaceae 47.4 39.5
KD-20 Sargassum yezoense Sargassaceae 80.5 68.8
KD-21 Gracilaria gracilis Gracilariaceae 40.6 13.4
KD-22 Chondrus ocellatus Gigartinaceae 17.4 <5
KD-23 Ecklonia cava Lessoniaceae 13.0 8.8
KD-24 Ecklonia cava Lessoniaceae 13.6 <5
KD-25 Ecklonia stolonifera Lessoniaceae 15.3 18.5
KD-26 Ecklonia stolonifera Lessoniaceae 6.0 12.2
KD-27 Undaria pinnatiﬁda Alariaceae 7.5 10.8
KD-28 Agarum clathratum Costariaceae 25.4 23.1
KD-29 Laurencia pinnata Rhodomelaceae <5 8.9
KD-30 Saccharina japonica Laminariaceae 38.5 8.9
KD-31 Polysiphonia morrowii Rhodomelaceae <5 14.0
KD-32 Corallina pilulifera Corallinaceae 50.4 23.7
KD-33 Colpomenia bullosa Scytosiphonaceae 17.0 <5
KD-35 Zostera marina Zosteraceae 19.3 11.6
KD-36 Chaetomorpha moniligera Cladophoraceae 14.6 <5
KD-37 Desmarastia ligulata Desmarestiaceae 25.2 <5
KD-38 Fucus distichus Fucaceae 8.9 5.6
KD-39 Grateloupia acuminata Halymeniaceae 10.2 19.9
KD-40 Sargassum fusiforme Sargassaceae 6.0 <5
KD-41 Derbesia marina Derbesiaceae 29.5 18.8
KD-42 Ulva clathrata Ulvaceae 26.4 28.4
KD-43 Dermonema pulvinatum Liagoraceae 72.1 35.6
KD-44 Laurencia nipponica Rhodomelaceae 26.0 19.3
KD-45 Polysiphonia morrowii Rhodomelaceae 56.7 12.6
KD-46 Polysiphonia morrowii Rhodomelaceae 24.3 24.9
KD-47 Codium fragile Codiaceae 14.0 18.7
KD-48 Grateloupia prolongata Halymeniaceae 57.8 21.4
KD-49 Prionitis cornea Halymeniaceae 56.2 33.6
KD-50 Sargassum thunbergii Sargassaceae 30.1 21.6
KD-51 Coccophora langsdorﬁi Sargassaceae 11.0 <5
KD-52 Nemalion vermiculare Liagoraceae 20.2 26.2
KD-53 Laurencia tropica Rhodomelaceae 19.0 7.4
KD-54 Chondrophycus intermedius Rhodomelaceae 24.6 16.4
KD-55 Gelidium amansii Gelidiaceae 42.2 17.0
KD-56 Spatoglossum paciﬁcum Dictyotaceae 6.4 26.0
KD-57 Polyopes lancifolius Halymeniaceae 44.3 14.7
KD-58 Codium fragile Codiaceae 27.6 <5
KD-59 Ulva intestinalis Ulvaceae 48.0 20.0
KD-60 Desmarastia ligulata Desmarestiaceae 49.4 17.7
KD-61 Gelidium amansii Gelidiaceae 32.3 19.6
KD-62 Papenfussiella kuromo Chordariaceae 40.2 11.3
KD-63 Ceramium boydenii Ceramiaceae 56.8 28.2
KD-64 Sargassum confusum Sargassaceae 17.6 <5
KD-65 Polysiphonia morrowii Rhodomelaceae 19.2 5.5
KD-66 Sargassum horneri Sargassaceae 7.9 13.1
KD-67 Dictyota dichotoma Dictyotaceae 17.6 17.3
KD-68 Sagassum sp. Sargassaceae 24.3 10.5
KD-69 Sagassum macrocarpum Sargassaceae <5 30.1
KD-70 Benzaitenia yenoshimensis Rhodomelaceae 40.2 29.9
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Table 1 (continued)
Code no. Scientiﬁc name Family name % Activation*
PPARa PPARc
KD-71 Bryopsis plumosa Bryopsidaceae 34.2 19.9
KD-72 Gelidium amansii Gelidiaceae 22.0 30.9
KD-73 Sagassum macrocarpum Sargassaceae 12.1 40.3
KD-74 Sargassum siliquastrum Sargassaceae 16.0 69.2
KD-75 Sargassum micracanthum Sargassaceae 22.6 60.1
KD-76 Cutleria cylindrica Cutleriaceae 46.0 77.1
KD-77 Chaetomorpha sp. Cladophoraceae 10.5 18.6
KD-78 Desmarestia viridis Desmarestiaceae 13.9 13.4
KD-79 Desmarestia viridis Desmarestiaceae 22.2 12.1
KD-80 Desmarestia viridis Desmarestiaceae 10.7 23.6
KD-81 Sargassum micracanthum Sargassaceae 24.8 34.4
KD-82 Desmarestia viridis Desmarestiaceae 26.2 <5
KD-83 Dictyota dichotoma Dictyotaceae 21.3 6.9
KD-84 Ahnfeltiopsis ﬂabelliformis Phyllophoraceae 22.5 22.9
KD-85 Myagropsis myagroides Sargassaceae 31.3 23.3
KD-86 Gracilaria gracilis Gracilariaceae 34.3 35.6
KD-87 Delesseria serrulata Delesseriaceae 31.6 21.4
KD-88 Sargassum yezoense Sargassaceae 70.0 71.9
KD-89 Spatoglossum paciﬁcum Dictyotaceae <5 15.0
KD-90 Ahnfeltiopsis ﬂabelliformis Phyllophoraceae 38.2 22.3
*Transcriptional activities of PPARa and -c in the presence of each natural marine product extract (10 lg/ml) were analyzed as described in Section 2.
Data were expressed as percentage activation against positive control (PPARa agonist; 10 lM Wy 14643 and PPARc agonist; 10 lM troglitazone).
Transcriptional activities of PPARa and -c increased 4.2- and 4.7-fold over each positive control, respectively. Data was expressed as the mean values
from two independent experiments.
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supernatants were reconstituted with the appropriate amount of water
and re-extracted with ethyl acetate. Ethyl acetate soluble fractions were
evaporated under a vacuum at 45 C and stored at 70 C until use.
2.2. Cell culture
3T3-L1 cells were cultured in Dulbeccos modiﬁed Eagles medium
(DMEM, Invitrogen, Carlsbad, CA), supplemented with 10% fetal bo-
vine serum (FBS, HyClone Laboratories, Logan, UT) and 1% penicil-
lin/streptomycin (Invitrogen) as described previously [14]. Two days
after conﬂuence, adipogenesis was induced by treating cells with a dif-
ferentiation mixture containing 5 lg/ml insulin, 0.25 lM dexametha-
sone and 0.5 mM 3-isobutyl-1-methylxanthine, all obtained from
Sigma Chemical (St. Louis, MO). Forty-eight hours later, the medium
was changed to 10% FBS–DMEM containing 5 lg/ml insulin, and,
after an additional 48 h, the medium was replaced with 10% FBS–
DMEM. Thereafter, the medium was changed with 10% FBS–DMEM
every 2 days. Test compounds were administered at the initiation of
diﬀerentiation and with every medium change for 8 days.
2.3. Oil Red O staining
After the induction of diﬀerentiation, the cells were stained with Oil
Red O (Sigma) [14]. Brieﬂy, cells were washed twice with phosphate-
buﬀered saline and ﬁxed with 10% formalin in phosphate-buﬀered sal-
ine for 1 h, and then washed three times with water. Cells were stained
with Oil Red O (six parts of 0.6% Oil Red O dye in isopropanol and
four parts of water) for 1 h. Excess stain was removed by washing with
water, and the stained cells were dried. The stained oil droplets were
dissolved in isopropanol containing 4% Nonidet P-40 and were quan-
tiﬁed by measuring the absorbance at 520 nm.
2.4. Luciferase reporter gene assay
CV-1 cells were seeded into 24-well plates and cultured for 24 h be-
fore transfection. The medium was then changed to 10% charcoal dex-
tran treated FBS–DMEM. Four hours later, a DNA mixture
containing the PPRE-luciferase reporter plasmid (0.3 lg), pcDNA3-
hPPAR-a/-c/-d (each 30 ng) and an internal control plasmid pRL-
SV-40 (5 ng) was transfected using TransFast transfection reagent
(Promega, Madison, WI). After 24 h of transfection, the cells were
incubated for an additional 24 h following treatment with positive con-
trol or the test materials. The luciferase activity of the cell lysates were
measured using the Dual-Luciferase Reporter Assay System accord-ing to the manufacturers instruction (Promega). Relative luciferase
activity was normalized for transfection eﬃciency using the corre-
sponding Renilla luciferase activity.
2.5. RT-PCR
Total RNA was extracted using the easy-BLUE total RNA extrac-
tion kit (iNtRON Biotechnology, Sungnam, Korea), and the integrity
of the RNA was checked by agarose gel electrophoresis and ethidium
bromide staining. One microgram of RNA was used as a template for
each reverse transcriptase (RT)-mediated PCR (RT-PCR) reaction
using the ImProm-II Reverse Transcription System (Promega) and
Taq polymerase (Solgent, Daejeon, Korea). The primer sets were the
following: adipose fatty acid-binding protein (aP2), forward 5 0-
ATGTGTGATGCCTTTGTGGGA-3 0 and reverse 5 0-TGCCCTTT-
CATAAACTCTTGT-3 0; PPAR-c, forward 5 0-TTCGCTGATGCA-
CTGCCTAT-3 0 and reverse 5 0-GCCAACAGCTTCTCCTTCTC-30;
resistin, forward 5 0-TCAACTCCCTGTTTCCAAATGC-3 0 and
reverse 5 0-TCTTCACGAATGTCCCACGA-3 0; C/EBPa, forward 5 0-
AGGTGCTGGAGTTGACCAGT-3 0 and reverse 5 0-CAGCCTAGA-
GATCCAGCGAC-3 0; adiponectin, forward 5 0-AGCCTGGAGA-
AGCCGCTTAT-3 0 and reverse 5 0-TTGCAGTAGAACTTGCCA-
GTGC-30; fatty acid synthase (FAS), forward 5 0-CTGCGTGGCTAT-
GATTATGGC-3 0 and reverse 5 0-CGTGAGGTTGCTGTCGTCT-
GT-3 0; adipocyte determination- and diﬀerentiation-dependent factor
1/sterol-regulatory element binding protein 1c (ADD1/SREBP1c),
forward 5 0-CAAACTGCCCATCCACCGAC-3 0 and reverse 5 0-
TGCCTCCTCCACTGCCACAA-3 0; glucose transporter 4 (GLUT4),
forward 5 0-CTTCTTTGAGATTGGCCCTGG-3 0 and reverse 5 0-
AGGTGAAGATGAAGAAGCCAAGC-30; and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), forward 5 0-ACCACAGTCCA-
TGCCATCAC-3 0 and reverse 5 0-TCCACCACCCTGTTGCTGTA-3 0.2.6. Quantitative real-time PCR
Real-time quantitative PCR analyses for the above adipogenic genes
were performed using the Rotor-Gene RG-3000 (Corbett Research,
Sydney, Australia). Reactions were performed in a 15 ll volume con-
taining 7.5 ll of 2· SYBR Green PCR Master Mix (Applied Biosys-
tems, Foster, CA), 0.6 ll of cDNA (corresponding to 60 ng of
reverse transcribed total RNA) and 5 pmol of each primer. PCR con-
ditions consist of a 10 min hot start at 95 C, followed by 40 cycles of
30 s at 95 C, 40 s at 58 C and 20 s at 72 C. Data were analyzed using
Rotor-Gene analysis software version 6.0 (Corbett Research).
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The Green PolarScreen PPAR Competitor Assay was used accord-
ing to the manufacturers instructions. This cell-free assay is based
on the puriﬁed recombinant human PPARc ligand-binding domain
and a selective ﬂuorescent PPARc ligand. The complex between the li-
gand and the ligand-binding domain exhibits high ﬂuorescence polar-
ization, which is lost upon ligand displacement by non-labeled
competitors. Millipolarization values for diﬀerent competitors were
determined with the Saﬁre2 Microplate Reader (Tecan, Salzburg,
Austria) with an excitation wavelength of 485 nm and emission wave-
length of 535 nm. IC50 value (concentration at which 50% of the ﬂuo-
rescent ligand is displaced) was determined using BioDataFit software
version 1.02 (Chang Bioscience, Castro Valley, CA).3. Results
3.1. Eﬀects of various natural marine product extracts on
PPARa/c transcriptional activity
Since natural marine products provide a rich source of
chemical diversity, they can be used to design and develop no-
vel useful therapeutic agents. Because PPARs play a crucial
role in adipocyte diﬀerentiation and potentiation of insulin
sensitivity, as well as in lipid metabolism [2,4,5], we ﬁrst tried
to search for active compounds from our natural marine prod-
uct library (Table 1) that could stimulate PPARa and PPARc
reporter gene activity. As shown in Table 1, several extracts
stimulated the transcriptional activity of PPARa and/or
PPARc. The following extracts show an increase of 50% orFig. 1. The extract of Sargassum yezoense stimulates adipocyte diﬀerentiation
the absence or presence of 10 lM troglitazone or 10 lg/ml KD-88. (A) Morph
the cellular triglyceride deposition with Oil Red O. (B) The stained oil drople
quantiﬁed by measuring the absorbance at 520 nm. Data were expressed as t
independent experiments. (C) mRNA levels of adipogenic marker genes from
diﬀerentiation mixture; DMT, diﬀerentiation mixture plus 10 lM troglitazonmore over the eﬀect of Wy 14643 on PPARa activation; Ahn-
feltiopsis ﬂabelliformis (KD-12), S. yezoense (KD-20, KD-88),
Corallina pilulifera (KD-32), Dermonema pulvinatum (KD-43),
Polysiphonia morrowii (KD-45), Grateloupia prolongata (KD-
48), Prionitis cornea (KD-49) and Ceramium boydenii (KD-
63). In addition, the extracts showing an increase of 50% or
more over the eﬀect of troglitazone on PPARc activation were
as follows; S. yezoense (KD-20, KD-88), S. siliquastrum (KD-
74), S. micracanthum (KD-75) and Cutleria cylindrical (KD-
76). Among them, the extract of S. yezoense led to increases
in transcriptional activation of both PPARa and PPARc with
the strongest potency (Table 1). These results imply that the
natural marine product extracts can be useful for the develop-
ment of speciﬁc agonists of PPARa and/or PPARc.
3.2. The extract of S. yezoense stimulates adipocyte
diﬀerentiation in 3T3-L1 cells
We next examined the eﬀect of the extract of S. yezoense on
adipocyte diﬀerentiation in 3T3-L1 cells. As shown in Figs. 1A
and B, treatment with the S. yezoense extract under diﬀerenti-
ation conditions led to a 5.9-fold increase in adipocyte diﬀeren-
tiation, which was comparable to the eﬀect of troglitazone
(7.3-fold); this was assessed by morphological changes based
on Oil Red O staining of cellular triglyceride content. This re-
sult implies that there are some active constituents inducing
PPAR activation in S. yezoense extract. Because the dramatic
changes in gene expression proﬁles during adipocyte diﬀerenti-in 3T3-L1 cells. 3T3-L1 cells were induced to diﬀerentiate for 8 days in
ological changes associated with adipogenesis were assessed by staining
ts were dissolved in isopropanol containing 4% Nonidet P-40 and were
he mean ± S.D. fold increase compared with untreated cells from three
total RNA were analyzed by RT-PCR as described in Section 2. DM,
e.
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levels of adipogenic genes. Culture of 3T3-L1 under diﬀerenti-
ation conditions dramatically induced the expression of adipo-
genic marker genes, including FAS, aP2, PPARc, resistin,
ADD1/SREBP1c, C/EBPa and adiponectin (Fig. 1C), which
was strongly potentiated by treatment with troglitazone
(Fig. 1C). This indicates that treatment with a diﬀerentiation
mixture is enough to convert 3T3-L1 preadipocyte cells to an
adipocyte phenotype through induction of adipogenic genes.
In addition, treatment of 3T3-L1 cells with S. yezoense extract
under diﬀerentiation conditions led to a dramatic increase in
expression of adipogenic genes compared with DM control
(Fig. 1C), which is in accordance with the observed increase
in triglyceride contents in diﬀerentiated cells and in the popu-
lation of Oil Red O-stained cells (Figs. 1A and B). This implies
that the extract of S. yezoense could potentiate adipocyte
diﬀerentiation resulting from the increased expression of
adipogenic genes.Fig. 2. SQA and SHQA from Sargassum yezoense act as PPARa/c dual
sargahydroquinoic acid (SHQA). (B) Transcriptional activation of PPARa a
were expressed as the mean ± S.D. fold increase compared with untreated
PPARa/c/d were used as positive controls (Wy 14643, troglitazone and G
Students t-test. (C) Binding aﬃnities of SQA and SHQA with PPARc we
described in Section 2.3.3. Sargaquinoic acid and sargahydroquinoic acid are active
ingredients of S. yezoense for PPARa/c activation
We isolated the active ingredients from S. yezoense able to
stimulate PPARa/c transcriptional activities. Two compounds
were isolated with solvent extraction, and reverse and normal
phase HPLCs, and their structures were analyzed by 1H/13C-
NMR and mass spectrometry; these compounds were identi-
ﬁed as sargaquinoic acid (SQA) and sargahydroquinoic acid
(SHQA) (Fig. 2A, Supplementary material). Although these
compounds had already been isolated and reported from Sar-
gassum species [16,17], their biological properties, especially
their potential for PPAR activation, were unknown. We there-
fore examined the eﬀects of SQA and SHQA on the transcrip-
tional activity of PPARs. As shown in Fig. 2B, SQA showed
similar dose-dependent increases in both PPARa and -c activa-
tion (2.6-fold and 3.0-fold increases, respectively). The eﬀect of
SHQA on PAPRa activation was higher (4.3-fold) than that
on PPARc (2.1-fold). However, these two compounds seemedagonists. (A) Chemical structures of sargaquinoic acid (SQA) and
nd -c by SQA or SHQA were analyzed as described in Section 2. Data
control cells from ﬁve independent experiments. Speciﬁc agonists for
W501516, respectively). *P < 0.05, compared to control group with
re measured using the Green PolarScreen PPAR competitor assay as
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vation by these compounds was less than 2.0-fold as well as
dose-dependency was not observed despite signiﬁcant activa-
tion of PPARd by SQA (Fig. 2B). These results indicate that
SQA and SHQA from S. yezoense act as PPARa/c dual ago-
nists, although their eﬃcacies are weaker than those of Wy
14643 and troglitazone.
Next, we examined whether SQA and SHQA directly bind to
PPARc using a PPARc competitor binding assay. This cell-
free competitor binding assay is based on the puriﬁed recombi-
nant human PPARc ligand-binding domain and a selective
ﬂuorescent PPARc ligand. The complex between the ligand
and the ligand-binding domain exhibits high ﬂuorescence
polarization, which is lost upon ligand displacement by non-la-
beled competitors. As shown in Fig. 2C, treatment with trog-
litazone led to a decrease in ﬂuorescence polarization with
IC50 of 658 nM. SQA bound to the receptor with IC50 ofFig. 3. SQA and SHQA enhance adipocyte diﬀerentiation and adipogenic gen
presence of 10 lM troglitazone, 10 l SQA or 10 lM SHQA. (A) Morpholog
cellular triglyceride deposition with Oil Red O. (B) The stained oil droplets
quantiﬁed by measuring the absorbance at 520 nm. Data were expressed as t
independent experiments. (C) Total RNA was extracted from diﬀerentiated 3
quantitative real-time PCR. Relative mRNA expression was expressed as th255 nM, higher than that of troglitazone; the IC50 value of
SHQA was 725 nM. Taken together, these ﬁndings suggest
that SQA and SHQA act as a PPARc agonist through direct
binding to the PPARc ligand-binding domain.
3.4. SQA and SHQA enhance adipocyte diﬀerentiation in 3T3-
L1
It has been well documented that PPARc agonists can en-
hance adipocyte diﬀerentiation through an increase in insulin
sensitivity by PPARc activation. To explore the potential ef-
fects of SQA and SHQA on adipogenesis, 3T3-L1 preadipo-
cytes were diﬀerentiated for 8 days, under diﬀerentiation
conditions in the presence of SQA or SHQA. As shown in
Fig. 3A, SQA and SHQA signiﬁcantly increased lipid accumu-
lation of adipocytes, which was comparable to the eﬀect of
troglitazone. To further characterize the adipogenic potential
of SQA and SHQA, cellular triglyceride contents were mea-e expression. 3T3-L1 cells were induced to diﬀerentiate for 8 days in the
ical changes associated with adipogenesis were assessed by staining the
were dissolved in isopropanol containing 4% Nonidet P-40 and were
he mean ± S.D. fold increase compared with untreated cells from three
T3-L1 cells at day 8. Expression levels of each gene were measured by
e mean ± S.D. fold increase compared with control cells.
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was increased by SQA and SHQA treatment, up to 5.6- and
6.3-fold, respectively (Fig. 3B), which was in accordance with
the result demonstrating SQA and SHQA cause lipid droplet
accumulation of adipocytes (Fig. 3A).
We next examined the eﬀect of SQA and SHQA on adipo-
genic transcription factors and marker gene expression. After
induction of adipocyte diﬀerentiation in the presence of SQA
or SHQA, we analyzed the mRNA levels of C/EBPa, PPARc,
aP2, adiponectin and resistin using real-time PCR. Treatment
with either SQA or SHQA during adipocyte diﬀerentiation led
to increases in mRNA levels of C/EBPa, PPARc, aP2, adipo-
nectin and resistin (Fig. 3C). In addition, SQA and SHQA
treatment led to an increase in the mRNA level for Glut4,
responsible for insulin-mediated glucose uptake, indicating
that insulin sensitivity of adipose tissue could be enhanced
by SQA and SHQA treatment. Collectively, SQA and SHQA
from S. yezoense enhance adipocyte diﬀerentiation in 3T3-L1
cells by increasing the expression of genes critical for adipocyte
phenotypes via PPARc activation.4. Discussion
We demonstrate here the potential of SQA and SHQA from
S. yezoense as novel PPARa/c dual agonists, which stimulate
adipogenesis caused by up-regulation of adipocyte speciﬁc
marker gene expression. This is the ﬁrst report of the adipo-
genic potential of these two compounds through PPARa/c
dual activation.
Natural marine products have attracted much attention as a
pharmacological source that can be used to develop novel ther-
apeutic agents because of distinct environments of marine life
and biological diversities of marine organisms [13]. Indeed, the
pharmacology of marine compounds in terms of anti-tumor,
anthelmintic, anti-bacterial, anti-coagulant, anti-diabetic,
anti-fungal, anti-inﬂammatory, anti-malarial, anti-platelet,
anti-protozoal, anti-tuberculosis and anti-viral activities have
been reported and reviewed [18,19]. In this study, we investi-
gate the ability of natural marine products to increase
PPARa/c transcriptional activities as promising therapeutic
targets for dyslipidemia and diabetes. There are enormous ef-
forts for the development of dual PPARa/c agonists to treat
diabetes as well as the associated dyslipidemia. As a result, sev-
eral candidates of dual PPARa/c agonist have been developed;
muraglitazar, tesaglitazar, KRP-297 (MK-767) and TAK-5595
[9,10]. However, further development of muraglitazar and
tesaglitazar failed at clinical trials, because of their unexpected
cardiovascular toxicities [11]. Therefore, it is noteworthy that
S. yezoense enhances the transcriptional activities of PPARa/
c as well as adipocyte diﬀerentiation (Table 1, Fig. 1). In addi-
tion to S. yezoense, several natural marine products show spe-
ciﬁc activation of PPARa or PPARc or activation of both
(Table 1), suggesting that natural marine products can be
developed as speciﬁc agonists of PPARa and/or PPARc.
Our data demonstrate SQA and SHQA to be active ingredi-
ents of S. yezoense, inducing PPARa/c activation as well as
adipogenesis (Figs. 2 and 3). Although SQA and SHQA had
previously been isolated and reported from Sargassum species,
and several associated pharmacological activities were evalu-
ated [16,17,20,21], this is the ﬁrst report of the adipogenic po-
tential of these two compounds through PPARa/c dualactivation. In addition, our data show that the eﬀects of
SQA and SHQA to induce PPARa/c activity are weaker than
those of the positive controls Wy 14643 or troglitazone; how-
ever the binding aﬃnity of SQA with PPARc (IC50 255 nM)
was 2.6-fold higher than that of troglitazone (IC50 658 nM),
and the binding aﬃnity of SHQA (IC50 725 nM) is similar to
that of troglitazone. At the present time, we do not know
the exact reason why SQA shows lower eﬃcacy than troglitaz-
one on PPARc transcriptional activity, despite its higher aﬃn-
ity with PPARc. Nevertheless, SQA and SHQA strongly
enhance adipocyte diﬀerentiation, similar to the eﬀect of trog-
litazone, resulting from increases in adipogenic gene expression
(Fig. 3). Collectively, these ﬁndings suggest that SQA and
SHQA from S. yezoense could be possible candidates as ther-
apeutic agents for the treatment of type-2 diabetes and dyslipi-
demia, and serve as novel lead compounds for further
development of PPARa/c dual agonists.
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